Barinthus Biotherapeutics plc. 8-K

What Happened
Barinthus Biotherapeutics plc (ticker: BRNS) announced in an 8‑K filed January 6, 2026 that on December 30, 2025 it received a Nasdaq notification that its American Depositary Shares (ADSs) closed below $1.00 per share for 30 consecutive business days and thus does not meet Nasdaq Listing Rule 5450(a)(1) (minimum bid price) for continued listing. The notice does not result in immediate delisting and the ADSs remain listed on the Nasdaq Global Market.

Key Details

• Nasdaq letter dated December 30, 2025 cited 30 consecutive business days below $1.00, triggering non‑compliance with Rule 5450(a)(1).
• The Company has an automatic 180‑calendar day compliance period under Nasdaq Rule 5810(c)(3)(A), until June 29, 2026, to regain compliance.
• To regain compliance the ADS closing bid must be at least $1.00 for a minimum of ten consecutive business days during the cure period.
• If not cured by June 29, 2026, the Company may be eligible for a second 180‑day period if certain requirements are met; the Company is evaluating options including a possible reverse stock split.
• 8‑K was signed by CEO William Enright on January 6, 2026.

Why It Matters
This notice signals a risk of potential future delisting if the ADS price does not recover, which can affect liquidity, investor access, and index or fund eligibility. The company currently remains listed and has until June 29, 2026 to meet Nasdaq’s $1.00 minimum bid requirement (ten consecutive business days). Investors should monitor the ADS price, company announcements about measures to regain compliance (such as a reverse stock split), and any further Nasdaq communications.